Regentis Biomaterials completes NYSE American IPO raising approximately $10 million at a $52 million post‑money valuation

"Amit, Pollak, Matalon & Co. represented Regentis Biomaterials Ltd. in its NYSE American IPO, which raised approximately $10 million at a $52 million post‑money valuation. The company's shares will trade under the ticker RGNT. Regentis develops GelrinC, an innovative hydrogel for cartilage repair."

Amit, Pollak, Matalon & Co. represented Regentis Biomaterials Ltd. in connection with the company’s NYSE American initial public offering. Regentis completed its IPO on the NYSE American, raising approximately $10 million at a post‑money valuation of approximately $52 million. The company’s shares will begin trading under the ticker RGNT. Regentis is a regenerative medicine company developing GelrinC®, an innovative hydrogel for cartilage repair, and the offering marks a significant step in the company’s progression from startup to a publicly traded life sciences enterprise. Amit, Pollak, Matalon & Co. represented Regentis Biomaterials Ltd. with a team composed by: Partner Adv. Ronen Kantor (Partner; Capital Markets, Hi‑Tech & Commercial Practice), Partner Adv. Racheli Cavallero (Partner), and Adv. Michael Misul (Capital Markets, Hi‑Tech & Commercial Practice).

Regentis Biomaterials completes NYSE American IPO raising approximately $10 million at a $52 million post‑money valuation

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads